BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
332.67
+11.28 (3.51%)
Nov 6, 2025, 4:00 PM EST - Market closed
BeOne Medicines AG Stock Forecast
Stock Price Forecast
The 10 analysts that cover BeOne Medicines AG stock have a consensus rating of "Strong Buy" and an average price target of $350, which forecasts a 5.21% increase in the stock price over the next year. The lowest target is $311 and the highest is $385.
Price Target: $350 (+5.21%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BeOne Medicines AG stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 7 | 7 | 7 | 8 | 8 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $350 → $383 | Buy | Maintains | $350 → $383 | +15.13% | Oct 20, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $345 → $385 | Buy | Maintains | $345 → $385 | +15.73% | Oct 8, 2025 |
| Barclays | Barclays | Buy Initiates $385 | Buy | Initiates | $385 | +15.73% | Sep 18, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $349 → $364 | Buy | Maintains | $349 → $364 | +9.42% | Aug 7, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $350 → $365 | Strong Buy | Maintains | $350 → $365 | +9.72% | Aug 7, 2025 |
Financial Forecast
Revenue This Year
37.64B
from 3.81B
Increased by 887.89%
Revenue Next Year
46.09B
from 37.64B
Increased by 22.45%
EPS This Year
1.04
from -6.12
EPS Next Year
3.13
from 1.04
Increased by 200.88%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 39.9B | 49.9B | |||
| Avg | 37.6B | 46.1B | |||
| Low | 36.0B | 43.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 947.0% | 32.5% | |||
| Avg | 887.9% | 22.5% | |||
| Low | 844.5% | 15.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.56 | 3.68 | |||
| Avg | 1.04 | 3.13 | |||
| Low | 0.49 | 2.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 253.3% | |||
| Avg | - | 200.9% | |||
| Low | - | 121.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.